Antares Pharma, Inc. (NASDAQ:ATRS) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, July 18th. The firm currently has a $3.42 price objective on the specialty pharmaceutical company’s stock. Vetr‘s target price would suggest a potential upside of 16.72% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Chardan Capital assumed coverage on Antares Pharma in a report on Friday, June 23rd. They set a “buy” rating and a $5.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a report on Friday, June 23rd. Finally, Raymond James Financial, Inc. assumed coverage on Antares Pharma in a report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 target price for the company. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.34.
Shares of Antares Pharma (NASDAQ ATRS) opened at 2.93 on Tuesday. The company’s 50-day moving average price is $3.14 and its 200-day moving average price is $2.77. Antares Pharma has a 52-week low of $1.03 and a 52-week high of $3.37. The stock’s market cap is $458.27 million.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The business had revenue of $13.42 million during the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. Analysts expect that Antares Pharma will post ($0.11) earnings per share for the current year.
In other Antares Pharma news, insider Fred M. Powell purchased 130,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were purchased at an average cost of $2.79 per share, with a total value of $362,700.00. Following the completion of the transaction, the insider now owns 331,434 shares of the company’s stock, valued at $924,700.86. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ATRS. Alliancebernstein L.P. acquired a new position in Antares Pharma during the second quarter valued at $119,000. Legal & General Group Plc acquired a new position in Antares Pharma during the second quarter valued at $120,000. MML Investors Services LLC raised its position in Antares Pharma by 228.2% in the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 30,000 shares during the last quarter. Credit Suisse AG acquired a new position in Antares Pharma during the first quarter valued at $146,000. Finally, National Planning Corp raised its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the last quarter. 31.70% of the stock is currently owned by hedge funds and other institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.